zalcitabine

We are zalcitabine CAS:7481-89-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:zalcitabine
CAS.NO:7481-89-2
Synonyms:ddCyd
[3H]-Zalcitabine
ddC
2',3'-DIDEOXYCYTIDINE
Zalcitabine
Molecular Formula:C9H13N3O3
Molecular Weight:211.21800
 
Physical and Chemical Properties:
Density:1.57
Melting point:217-218ºC
Boiling point:415ºC
Flash point:204ºC
 
Specification:
Appearance:White to off-white crystalline powder
Assay(HPLC):≥98.0%
Moisture:≤1.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:A pyrimidine nucleoside analogue with antiviral activity.

zalcitabine


Related News: Retrogenix’s proprietary cell microarray technology provides a fast, accurate and effective solution for determining the primary target and secondary target (off-target) activities of antibodies, proteins, cell therapies, small molecules and viruses.Ácido 4-fluorobenzoico CAS:456-22-4 The policy-oriented emphasis on the medical and pharmaceutical industries and the direct support for the chemical raw material pharmaceutical industry have created a good political environment for the development of related enterprises and laid the foundation for the rapid development of the chemical raw material pharmaceutical industry. The good development prospects of the chemical raw material pharmaceutical industry will be passed directly to the upstream raw material industry, which will help stimulate the demand for the pharmaceutical intermediate market.22918-01-0 Therefore, the R & D capabilities and registration capabilities of API companies have become the core factors of competition.2-hydrazinoethanol CAS:109-84-2 Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend.The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.

Related Products
Product Name
allidochlor View Details
tyramine View Details
2-Allyl-4-hydroxy-3-methyl-2-cyclopenten-1-one View Details
Methyl (2E)-3-[3-(trifluoromethyl)phenyl]acrylate manufacturer 2R,3R)-rel-1-(Dimethylamino)-3-(3-methoxyphenyl)-2-methylpentan-3-ol hydrochloride manufacturer 1-Bromo-4-nitrobenzene manufacturer spiro[1-azabicyclo[2.2.2]octane-3,2′-oxirane],hydrochloride manufacturer N-Ethylethylenediamine manufacturer